Microdosing: Updating its role in developing new medicines

One of yesterday's most promising new tools for speeding the development of new medicines—"microdosing"—has found niches in that process today, and they include uses unanticipated a decade ago. That topic, an update on microdosing, is the cover story in the current edition of Chemical & Engineering News. C&EN is the weekly newsmagazine of the American Chemical Society, the world's largest scientific society.

C&EN Senior Editor Celia Henry Arnaud explains that microdosing offered promise for helping pharmaceutical companies identify potential failures earlier, before starting full-fledged of a potential new drug. It involves giving subtherapeutic doses—1 percent of the full dose—to human volunteers after minimal animal testing. Scientists then would use the results to determine whether to move ahead with expensive safety testing in traditional Phase 1 clinical trials. Microdosing promised to become a standard part of drug development, adding a new so-called Phase 0 to that process.

The article points out that occasional Phase 0 clinical trials do, indeed, take place. But microdosing most often is used in "absolute bioavailability studies," done in parallel with standard clinical trials to determine how much of the drug actually reaches its target tissue to treat the disease. Other uses of microdosing may emerge in the years ahead, the article notes.

More information: "Diverging Roads for Microdosing"—cen.acs.org/articles/91/i3/Sea… Diverging-Roads.html

add to favorites email to friend print save as pdf

Related Stories

Nanomedicines promise fewer side effects in treating cancer

Jun 06, 2012

A new generation of cancer treatments based on nanotechnology is making its way out of the laboratory and into the clinic with the promise of targeting cancer cells while steering clear of healthy tissue, according to the ...

Recommended for you

Health care M&A leads global deal surge

19 hours ago

In a big year for deal making, the health care industry is a standout. Large drugmakers are buying and selling businesses to control costs and deploy surplus cash. A rising stock market, tax strategies and ...

US approves new, hard-to-abuse hydrocodone pill (Update)

Nov 20, 2014

U.S. government health regulators on Thursday approved the first hard-to-abuse version of the painkiller hydrocodone, offering an alternative to a similar medication that has been widely criticized for lacking ...

Soaring generic drug prices draw Senate scrutiny

Nov 20, 2014

Some low-cost generic drugs that have helped restrain health care costs for decades are seeing unexpected price spikes of up to 8,000 percent, prompting a backlash from patients, pharmacists and now Washington ...

Only half of patients take their medications as prescribed

Nov 20, 2014

The cost of patients not taking their medications as prescribed can be substantial in terms of their health. Although a large amount of research evidence has tried to address this problem, there are no well-established ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.